| Histone modifications and cancer JE Audia, RM Campbell Cold Spring Harbor perspectives in biology 8 (4), a019521, 2016 | 861 | 2016 |
| The promise and peril of chemical probes CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ... Nature chemical biology 11 (8), 536-541, 2015 | 838 | 2015 |
| The protein kinase Cβ–selective inhibitor, enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon … JR Graff, AM McNulty, KR Hanna, BW Konicek, RL Lynch, SN Bailey, ... Cancer research 65 (16), 7462-7469, 2005 | 512 | 2005 |
| Crystal structure of the human PRMT5: MEP50 complex S Antonysamy, Z Bonday, RM Campbell, B Doyle, Z Druzina, T Gheyi, ... Proceedings of the National Academy of Sciences 109 (44), 17960-17965, 2012 | 368 | 2012 |
| Synthesis and activity of new aryl-and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain JS Sawyer, BD Anderson, DW Beight, RM Campbell, ML Jones, ... Journal of medicinal chemistry 46 (19), 3953-3956, 2003 | 299 | 2003 |
| Synthesis, biological activity and conformational analysis of cyclic GRF analogs AM Felix, EP HEIMER, CTSO WANG, TJ LAMBROS, A FOURNIER, ... International journal of peptide and protein research 32 (6), 441-454, 1988 | 263 | 1988 |
| HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. K Ito, HJ Bian, M Molina, J Han, J Magram, E Saar, C Belunis, DR Bolin, ... The Journal of experimental medicine 183 (6), 2635-2644, 1996 | 245 | 1996 |
| New assay technologies for high-throughput screening L Silverman, R Campbell, JR Broach Current Opinion in Chemical Biology 2 (3), 397-403, 1998 | 209 | 1998 |
| Kinomics: characterizing the therapeutically validated kinase space M Vieth, JJ Sutherland, DH Robertson, RM Campbell Drug discovery today 10 (12), 839-846, 2005 | 206 | 2005 |
| Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene X Gong, J Du, SH Parsons, FF Merzoug, Y Webster, PW Iversen, LC Chio, ... Cancer discovery 9 (2), 248-263, 2019 | 191 | 2019 |
| Cancer epigenetics drug discovery and development: the challenge of hitting the mark RM Campbell, PJ Tummino The Journal of clinical investigation 124 (1), 64-69, 2014 | 185 | 2014 |
| Evolution of the growth hormone-releasing factor (GRF) family of peptides. RM Campbell, CG Scanes Growth regulation 2 (4), 175-191, 1992 | 173 | 1992 |
| Sirtuin 1 (SIRT1) the misunderstood HDAC W Stünkel, RM Campbell Journal of biomolecular screening 16 (10), 1153-1169, 2011 | 171 | 2011 |
| Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth M Dewaele, T Tabaglio, K Willekens, M Bezzi, SX Teo, DHP Low, CM Koh, ... The Journal of clinical investigation 126 (1), 68-84, 2016 | 167 | 2016 |
| Synthesis and activity of new aryl-and heteroaryl-substituted 5, 6-dihydro-4H-pyrrolo [1, 2-b] pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain JS Sawyer, DW Beight, KS Britt, BD Anderson, RM Campbell, ... Bioorganic & medicinal chemistry letters 14 (13), 3581-3584, 2004 | 166 | 2004 |
| Synthesis, Structure− Activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors G Zhu, SE Conner, X Zhou, C Shih, T Li, BD Anderson, HB Brooks, ... Journal of medicinal chemistry 46 (11), 2027-2030, 2003 | 158 | 2003 |
| Imidazolyl benzimidazoles and imidazo [4, 5-b] pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties M Mader, A de Dios, C Shih, R Bonjouklian, T Li, W White, BL de Uralde, ... Bioorganic & medicinal chemistry letters 18 (1), 179-183, 2008 | 152 | 2008 |
| LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity ZQ Bonday, GS Cortez, MJ Grogan, S Antonysamy, K Weichert, ... ACS medicinal chemistry letters 9 (7), 612-617, 2018 | 149 | 2018 |
| LLY-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2 H Nguyen, A Allali-Hassani, S Antonysamy, S Chang, LH Chen, C Curtis, ... Journal of Biological Chemistry 290 (22), 13641-13653, 2015 | 141 | 2015 |
| Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity RM Campbell, BD Anderson, NA Brooks, HB Brooks, EM Chan, A De Dios, ... Molecular cancer therapeutics 13 (2), 364-374, 2014 | 125 | 2014 |
